
PROFOUND MEDICAL CORP.

Pioneering a new standard of care in the treatment of prostate cancer



Forward-Looking Statements

This presentation and oral statements made during this meeting regarding Profound and its business which may include, but are not limited to, the expectations regarding the efficacy of Profound's technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this presentation may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition.

Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

Investment Highlights

- Commercializing a new, minimally invasive technology (TULSA) for the ablation of targeted prostate tissue
- Received CE Mark approval in April 2016 for TULSA-PRO[™]
- Large and growing market opportunity; significant unmet medical need
- Strong IP portfolio
- Attractive razor/razor blade revenue model
- MRI installed base with strong partnerships
- Near- and mid-term milestones offer value inflection opportunities




Prostate Cancer Incidence

1 in 7 men will be diagnosed with prostate cancer in their lifetime



Large & Growing Market



500,000 new patients per year 850,000 procedures per year

US\$40 Billion Market


- Surgery \$18B
- Radiation \$20B
- HIFU \$0.9B
- Cryo \$0.7B



The Problem

TSXV:PRN

While prostate cancer survival rates are high, the current therapies have undesirable complication rates





Potosky et al, "Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study (PCOS)," Journal of the National Cancer Institute, 96(18): 1358-1367 (2004)



What If?

What if you could treat localized prostate cancer in 2 hours?

- Minimally invasively
- With real-time image guidance
- In a single treatment
- With the same or even better outcomes than surgery or radiation




Our Solution






Our Solution









TULSA-PRO Procedure




1. Patient on MRI bed



3. Probe inserted into patient urethra



2. Patient in MRI scanner




4. MR imaging of prostate in slices.



10


Proven Accuracy

Testing in prostates showed excellent agreement between MRI temperature measurements, histology and contrast-enhanced MRI




MR Thermometry

- 0% cell kill
- all tissues outside are normal



Histology

- 100% cell kill
- all tissues inside are killed



Contrast-enhanced MRI


Prostate region of non-perfusion



11

Reduced Tissue Damage

Our preclinical study observed 83% of urethral tissue was preserved after treatment




Inside-Out





Lower Complication Rates

Profound's technology results in fewer significant complications





13

TSXV:PRN

*Thompson (Chair) et al for AUA Prostate Cancer Clinical Guideline Update Panel (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. The Journal of Urology 177(6): 2106-31 *PMI 12-month Phase 1 Trial, GCP-10102 Table 10. The Phase I trial has demonstrated that MRI-guided TULSA provides accurate treatment planning, real-time thermal dosimetry and precise control of prostate ablation to within 1.3 mm, with a well-tolerated side-effect profile.

Outcomes:

- 30 patients treated with at least 12 month follow-up
- No intraoperative complications, no rectal injury or fistula
- Erectile dysfunction rate of 8% (IIEF item $2 \ge 2$)
- At 12 months, only 1 patient (3%) with Grade 1 urinary incontinence (no pads)
- Functional quality-of-life outcomes back to baseline levels



Tissue Affected

Current techniques may damage tissue far outside the therapy target area, or risk damage to critical structures

Radiation	HIFU	Radical Prostatectomy	TULSA-PRO [™]
 Non-invasive Outside-In Risk associated with treatment of surrounding tissue High rate of side effects, including damage to bowel 	 Non-invasive Outside-In (Transrectal) High rate of side effects, including thermal damage to bowel Limited to average or smaller size prostates 	 Invasive surgical technique Removes the gland and related tissues High rates of side effects such as incontinence and impotency Success related to skill of surgeon 	 Non-invasive Inside-Out (Trans-urethral) Precisely treats prostate tissue with minimal damage to nearby critical structures Low rate of complications





Advantages

- Safe, fast and accurate
- Millimeter accuracy ablates cancerous tissue while sparing critical structures
- Quick procedure with single treatment and rapid recovery time
- Minimally-invasive using thermal ablation to heat prostate from inside-out
- Guided by real-time MR imaging with temperature (thermometry) feedback
- Technology compatible with leading MRI platforms






Opportunity is Well Protected

Strong IP Portfolio:

- 6 patents issued in the United States •
- 6 patents pending in the United States ۲
- 9 patents pending foreign applications ۲

	(12) United States Patent			0) Patent		US 7,771,418 B2	
Chopra et al.		.(4	(45) Date of Patent: Aug. 10, 2010				
(54)	TREATM	ENT OF I	ISEASED TISSUE USIN	G.	6.517.306 BI	3/2003	Budette et al
	CONTRO	LLED UL	TRASONIC HEATING		6.542,767 Bt		McNichols et al 600/407
					6,559,644 B2	5/2003	Froundlich et al
(75)	Inventors:		pra, Toronio (CA); Micha		6,582,381 B1		Yehezkeli et al 601/2
			Toronto (CA); Mathieu		6,589,174 BL*		Chopra et al 600/439
		Bartnyk,	Toronio (CA)		6,618,608 B1		Wetkins et al 600/412
100	028328207	1.5.1.5.2.2			6,618,620 BI		Freundlich et al
(73)	Assignee:		ok Health Sciences Centre		6,623,430 BI		Slayton et al 600/4391
		Teromto, C	N (CA)		6,671,535 B1		McNichels et al 600/407
161	Notice:	Colliger to.	any disclaimer, the term of		6,692,450 BI		Coloman 601/3
2.1	Typinet.		extended or adjusted under	10.00	6,735,461 B2		Vitek et al
			k(h) by 1522 days.		6,746,465 B2		Diederich et al
		trants to	(a) by toxy cays.		6,755,849 BI		Growda et al
(21)	Appl. No.:	11/076,66	3		50193682 A1		Torchia et al
					40013970 Al		Makin
(22)	Filed:	Mar. 9, 20	05		P0018265 AL		Makin et al
					40018270 At 40036706 At		Makin et al
(65)		Prior I	ublication Data	2000	0036706 AL	2/2003	Slayton et al 600/439
	US 2006/0	206105 A1	Sep. 14, 2006				
(51)	Int. CL				(Continued)		tinoed)
Gil	A61B 18A	W I	2006.01)		OTHER PUBLICATIONS		BLICATIONS
(52)			606/28: 606	(27 Chim	and that the	-	281-1286 (2000)
(58)	Field of C	lassificatio	a Search 607	07. Catogo	a se al report ra	ar avior	201-1200 (2020).
607/101, 102, 105; 606/27; 601/2; 600/439,		139,		(Con	tinued)		
	600/411		411 main	w Examiner-	B D.e	108.000	
	See applic	stion file fo	r complete search history.	17300	n's Drawwei-	-Roy D v	Jacovati
(55)		Referes	ices Cited	(57)		ABST	RACT
	11	S PATENT	DOCUMENTS				
				The p	resent inventi-	on provid	es a method and apparatus for
	5,295,484 A		Marcus et al 128/69		sing and cout	rolling th	ermal therapy to a volume of
	5,553,618 A		Suzuki et al 600				the invention includes using
	5,620,479 A 5,647,361 A		Diederich				puts to determine an acoustic
	5,733,315 A		Durckette et al		(altrasonic) treatment regime employing interstitial ultra		
	6.050.943 A		Slayton et al	Strand.			roquired therapeutic tempera-
	6.122.551 A	9/2000	Rudie et al		r thermal dose	to the aff	ected region in a body or organ.
	6,379,320 Br		Lafon et al		3 surveys aspects of the treatment that can be controlled include individual treatment of the controlled include.		
	6,418,337 B		Torches et al	ALL IDCOVE			at operating power and fre-
	6.490.488 B1 12/2002 Rodie et al		102 quene		e rate of e	poling and rotation of the entire	
				alor.			
	6516.2H B		Acker et al				
	6.522,142 B	2/2003	Fisuadich 324	315	30 CI	aims, 12	Drawing Sheets



17



Strong Market Access Through Key Partnerships

PHILIPS

Joint Development Agreement announced July 2015 to support TULSA technology on Philips' Ingenia and Achieva 3T MRI systems

SIEMENS

Strategic Collaboration Agreement announced March 2016 to co-market and co-sell into the Siemens installed base of customers; each partner will invest \$2 million in marketing, educational and sales activities



Strong Leadership

Executive Team	
Steven Plymale	CEO (Xltek, CryoCath, Cedara, Claron, Bluehaven)
Ron Kurtz	VP, Engineering (Xltek)
Goldy Singh	VP, Quality & Regulatory Affairs (Xltek, C.R. Bard, Philips Medical, Natus Medical Inc.)
Hartmut Warnken	VP, International Sales (IMRIS Pte. Ltd., IMRIS Germany GmbH, IMRIS KK Japan)

Board of Directors	
Jean-François Pariseau	Partner, BDC Venture Capital
Damian Lamb	Co-Founder & Managing Director, Genesys Capital Partners
Steven Plymale	CEO, Profound Medical Corp.
William E. Curran	Previously President & CEO, Philips Electronics North America
Arun Menawat	President & CEO, Novadaq Technologies Inc.
Jonathan Goodman	President & CEO, Knight Therapeutics



Solid Path to Commercialization





20



Recent & Upcoming Milestones

- Received CE Mark approval in April 2016 for TULSA-PRO[™]
- Sale of first TULSA-PRO[™] to ResoFus Alomar in Spain in April 2016
- Pivotal Trial commencement
- Expansion of strategic collaborations / distributor partnerships
- Commercial launch Canada
- Solidify reimbursement pathway



In Conclusion

- TULSA poised to be a game changer in the clinical management of patients by ablation of targeted prostate tissue
- Large and growing market opportunity; significant unmet medical need
- Near- and mid-term milestones offer multiple value inflection opportunities
- Technology well protected by strong IP portfolio
- CE Mark obtained
- Attractive razor/razor blade revenue model
- Well established care delivery infrastructure
- Proven leadership team

'A GAME CHANGER'

In the clinical management of prostate care



22

Capitalization

Exchange & Ticker	TSXV: PRN	
Cash (@ December 31, 2015	\$20.5MM	
Debt: FedDev HTX Knight	\$0.8MM \$1.5MM \$4.0MM	
Common Shares (@ Dec 31 Basic, Fully Diluted	39.5MM; 43.8MM	
Significant Shareholders:	BDC Genesys Knight	24.8% 23.1% 7.7%



PROFCUND MEDICAL^{Corp.}



profoundmedical.com | 647-476-1350